Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
432.89 (USD) • At close September 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 180.133 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.584 | 14.803 | 144.245 | 2.615 | 0.743 | 0 | 0 | 0.173 | 1.304 | 0 | 0 |
| Cost of Revenue
| 7.329 | 0.527 | 0.467 | 0.405 | 0.471 | 0.112 | 0.096 | 0.077 | 0 | 0 | 0.673 | 0.516 | 0.738 | 1.464 | 0 | 0 | 0 | 0 | 3.655 | 0 | 3.13 | 0 | 0 | 0 |
| Gross Profit
| 172.804 | -0.527 | -0.467 | -0.405 | -0.471 | -0.112 | -0.096 | -0.077 | -0 | 0 | -0.673 | -0.516 | -0.738 | 6.12 | 0 | 0 | 0 | 0 | -3.655 | 0 | -2.957 | 1.304 | 0 | 0 |
| Gross Profit Ratio
| 0.959 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0.807 | 0 | 0 | 0 | 0 | 0 | 0 | -17.092 | 1 | 0 | 0 |
| Reseach & Development Expenses
| 236.718 | 271.823 | 245.441 | 205.164 | 184.809 | 72.324 | 25.389 | 24.39 | 15.934 | 54.218 | 68.205 | 71.86 | 49.412 | 41.464 | 40.252 | 51.054 | 81.581 | 52.025 | 50.503 | 59.901 | 38.136 | 24.337 | 7.292 | 0.277 |
| General & Administrative Expenses
| 0 | 108.146 | 48.13 | 37.318 | 21.864 | 22.648 | 15.293 | 7.672 | 9.29 | 13.392 | 15.746 | 15.699 | 11.676 | 11.552 | 11.449 | 12.651 | 14.742 | 14.934 | 8.648 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 435.057 | 108.146 | 48.13 | 37.318 | 21.864 | 22.648 | 14.971 | 7.672 | 9.29 | 13.392 | 15.746 | 15.699 | 11.676 | 11.552 | 11.449 | 12.651 | 14.742 | 14.934 | 8.648 | 11.279 | 7.383 | 5.261 | 0 | 0.124 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 670.679 | 379.969 | 293.104 | 241.577 | 205.849 | 94.86 | 40.36 | 31.809 | 24.981 | 3.171 | 83.278 | 87.043 | 60.35 | 51.552 | 49.768 | 61.242 | 96.106 | 63.608 | 55.496 | 68.725 | 43.972 | 29.598 | 7.292 | 0.401 |
| Operating Income
| -497.875 | -380.496 | -293.571 | -241.982 | -206.32 | -94.972 | -40.456 | -31.886 | -24.982 | -3.171 | -83.951 | -87.559 | -61.088 | -45.432 | -36.898 | 80.54 | -93.708 | -66.216 | -59.151 | -71.18 | -45.346 | -28.294 | -36.264 | -0.401 |
| Operating Income Ratio
| -2.764 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -414.565 | -5.991 | -2.493 | 0.558 | -35.835 | -89.12 | 0 | 0 | -262.116 | -21.698 | 0 | 0 |
| Total Other Income Expenses Net
| 31.983 | 6.866 | -1.779 | 0.136 | 4.076 | 11.024 | 7.645 | 0.732 | -1.406 | -3.674 | -2.21 | -2.633 | -1.702 | -1.948 | -0.569 | -1.452 | 1.09 | 2.721 | 1.881 | 2.317 | -0.588 | 0.416 | -18.088 | 0 |
| Income Before Tax
| -465.892 | -373.63 | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 | -31.154 | -26.388 | -68.671 | -86.161 | -90.192 | -62.79 | -47.38 | -37.467 | 79.088 | -92.618 | -63.495 | -59.129 | -68.863 | -45.934 | -27.878 | -54.352 | 0 |
| Income Before Tax Ratio
| -2.586 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -427.143 | -6.247 | -2.531 | 0.548 | -35.418 | -85.458 | 0 | 0 | -265.514 | -21.379 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -18.198 | 0.381 |
| Net Income
| -465.892 | -373.63 | -295.35 | -241.846 | -202.244 | -83.948 | -32.811 | -31.154 | -26.388 | -6.845 | -86.161 | -90.192 | -62.79 | -47.38 | -37.467 | 79.088 | -92.618 | -63.495 | -57.27 | -68.863 | -45.934 | -27.878 | -36.154 | -0.381 |
| Net Income Ratio
| -2.586 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -427.143 | -6.247 | -2.531 | 0.548 | -35.418 | -85.458 | 0 | 0 | -265.514 | -21.379 | 0 | 0 |
| EPS
| -21.9 | -19.99 | -17.23 | -14.63 | -13.09 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.55 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| EPS Diluted
| -21.9 | -19.99 | -17.23 | -14.63 | -13.09 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.2 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| EBITDA
| -450.125 | -360.391 | -290.919 | -241.441 | -201.773 | -83.836 | -32.715 | -31.077 | -25.175 | -3.233 | -83.278 | -87.043 | -60.203 | -43.968 | -34.965 | 81.863 | -89.412 | -60.144 | -53.615 | -66.408 | -44.387 | -27.288 | 10.796 | -0.401 |
| EBITDA Ratio
| -2.499 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -409.544 | -5.797 | -2.362 | 0.568 | -34.192 | -80.948 | 0 | 0 | -256.572 | -20.926 | 0 | 0 |